Anti-PD-1 Antibody Carrizumab combined with FLOT versus FLOT in neoadjuvant treatment of gastric or gastroesophageal junction adenocarcinoma: a randomized, single-center and controlled trial

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

13 Sep 2022 Results (n=63; From January 15 2020 to January 21, 2022) comparing the safety and efficacy of camrelizumab combined with chemotherapy versus chemotherapy alone as the neoadjuvant therapy for patients with resectable locally advanced and gastroesophageal junction adenocarcinoma, presented at the 47th European Society for Medical Oncology Congress.
07 Jun 2022 Results (n=61) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
19 Jul 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com